<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783107</url>
  </required_header>
  <id_info>
    <org_study_id>0611109</org_study_id>
    <nct_id>NCT00783107</nct_id>
  </id_info>
  <brief_title>Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>Clinical Investigation of Aerosol Immunotherapy in COPD: A Phase I Placebo-Controlled Dose Escalation/Deescalation Trial of Aerosol Cyclosporine (CyIS) in Patients With Gold Stage III Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, Phase I dose escalation-deescalation protocol (DEP) of&#xD;
      cyclosporine inhalation solution in patients with Gold Stage III chronic obstructive&#xD;
      pulmonary disease.&#xD;
&#xD;
      The purpose of the study is to evaluate the safety and effectiveness of aerosolized&#xD;
      Cyclosporine in treating COPD.&#xD;
&#xD;
      The specific aims of the study are:&#xD;
&#xD;
        1. To identify the short term (28 day) safety profile of CyIS immunotherapy in severe COPD&#xD;
           (GOLD III) patients with particular attention to airway reactivity and infection risk.&#xD;
&#xD;
        2. To identify the pharmacokinetic-pharmacodynamic relationship of CyIS using peripheral&#xD;
           blood markers of an adaptive immune response as endpoints in subjects with severe COPD&#xD;
           (GOLD III) treated short-term.&#xD;
&#xD;
      Subjects between 45 and 70 years of age with a confirmed diagnosis of COPD, Gold Stage III,&#xD;
      and meet all the study requirements, will be enrolled in this study. A total of 24 subjects&#xD;
      of either sex will be enrolled in this study. A total of 4 subject cohorts (n=6) will&#xD;
      participate in the protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and effectiveness of aerosol cyclosporine (CyIS) an immunomodulating therapeutic in treating COPD</measure>
    <time_frame>Short term (28 day) safety profile</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Cyclosporine Inhalation Solution, Once Daily</description>
    <arm_group_label>Cyclosporine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 45 and 70 years.&#xD;
&#xD;
          -  A confirmed diagnosis of COPD, Gold Stage III, using current accepted diagnostic&#xD;
             criteria, including clinical/laboratory findings, pulmonary function tests, and&#xD;
             appropriate history to exclude other disorders that could explain their lung disease.&#xD;
&#xD;
          -  Subjects agree to maintain a stable medication regimen in the absence of a disease&#xD;
             flare&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2.&#xD;
&#xD;
          -  pCO2 &lt; 45 mm Hg, room air oxyhemoglobin saturation &gt; 85%&#xD;
&#xD;
          -  A willingness to participate in all portions of the protocol, including serial&#xD;
             bronchoscopy, requisite surveillances, and ancillary immunologic studies in follow-up&#xD;
             visits at this institution.&#xD;
&#xD;
          -  For woman of childbearing age, a negative pregnancy test, and a willingness to use two&#xD;
             methods of contraception, or abstinence, and undergo monthly pregnancy testing.&#xD;
&#xD;
          -  Elevated T-cell cytokine gene expression, defined as baseline values &gt; the mean of the&#xD;
             pilot Gold 0-1 study population for one variable (CD4+IL-2 &gt;23%, CD8+IFN-g &gt;17%,&#xD;
             CD8+MHC &gt; 6%, or CD8 TGF-b).&#xD;
&#xD;
          -  An ability and willingness to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Three, or more exacerbations of lower respiratory disease in the past year requiring&#xD;
             systemic corticosteroids, or one exacerbation requiring hospitalization in the past 6&#xD;
             months&#xD;
&#xD;
          -  Intubation for COPD, or other cause of respiratory failure in the past year&#xD;
&#xD;
          -  Use of immunosuppressive therapy (including oral prednisone), other than aerosolized&#xD;
             corticosteroids, anytime within three months prior to participation&#xD;
&#xD;
          -  Evidence for an opportunistic infection/colonization of the airways, i.e.,&#xD;
             non-bacterial&#xD;
&#xD;
          -  Use of aerosolized corticosteroids with an inability to maintain inhaled&#xD;
             corticosteroid therapy dosing without change during the study interval&#xD;
&#xD;
          -  Evidence for systemic illness including hematologic disorders (defined by an absolute&#xD;
             neutrophil count (ANC) &lt; 4000 /mL and platelets &lt; 120,000/mL), renal insufficiency&#xD;
             (serum creatinine &gt; 2.0 mg/dL), cirrhosis, or hepatic insufficiency (total bilirubin,&#xD;
             or alkaline phosphatase &gt; 1.5 x normal, SGOT, or SGPT &gt; 1.2 x normal values), or a&#xD;
             coagulopathy (INR &gt; 1.4), seizure disorder.&#xD;
&#xD;
          -  Evidence for systemic abnormal renal function manifested by uncontrolled hypertension&#xD;
             (systolic blood pressure &gt; 160mmHg or diastolic blood pressure &gt;90mmHg), hyperkalemia&#xD;
             (serum creatinine &gt; 5.0 meq/dl, and/or elevated serum creatinine above the normal&#xD;
             range for the subject's age.&#xD;
&#xD;
          -  Evidence of coronary artery disease by history, e.g., angina or history of myocardial&#xD;
             infarction within the past 12 months, unless corrected by CABG within &lt; 5 years, and&#xD;
             asymptomatic since&#xD;
&#xD;
          -  Pregnant or breast feeding females or women of childbearing potential not practicing&#xD;
             birth control during and for 6 months following treatment, or fertile and sexually&#xD;
             active males unwilling to use contraceptive techniques during and for 6 months&#xD;
             following treatment&#xD;
&#xD;
          -  Positive HIV, or hepatitis B or C serology, or another active infection&#xD;
&#xD;
          -  Current or past history of cancer excluding basal or squamous cell skin cancer&#xD;
&#xD;
          -  Undiagnosed pulmonary nodule requiring diagnostic evaluation&#xD;
&#xD;
          -  Weight loss &gt; 10% usual body weight over the past 6 months or a BMI &lt; 18&#xD;
&#xD;
          -  Known hypersensitivity or allergy to propylene glycol, CsA, or lidocaine&#xD;
&#xD;
          -  Concurrent enrollment or participation within the prior month in other clinical trials&#xD;
&#xD;
          -  Greater than 15% or 200 ml reduction in FEV1 post test dose propylene glycol&#xD;
             administration&#xD;
&#xD;
          -  Known medical or psychological condition (severe personality disorder or mental&#xD;
             illness) that would not permit the subject to complete the trial or sign informed&#xD;
             consent&#xD;
&#xD;
          -  Autoimmune disorders or other disorders with suspected systemic immune involvement&#xD;
&#xD;
          -  Active smoking history or urinary cotinine &gt; 2.&#xD;
&#xD;
          -  Hypersensitivity to midazolam or narcotics which would not allow bronchoscopy sedation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Donahoe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gold Stage III COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

